<DOC>
	<DOCNO>NCT00700713</DOCNO>
	<brief_summary>Study evaluate persistence antibody approximately three year initial dose Menactra® vaccine toddler participate study MTA26 ( NCT00643916 ) age-matched Menactra naive participant . Objectives : - To assess persistence antibody responses three year one two dos Menactra® vaccine subject participate study MTA26 . - To describe antibody response single dose Menactra® vaccine subject previously receive one two dos Menactra® vaccine Menactra® vaccine-naïve subject . - To describe safety profile single dose Menactra® vaccine subject .</brief_summary>
	<brief_title>Antibody Persistence Booster Dose Response Subjects Who Received Menactra® Three Years Earlier Study MTA26</brief_title>
	<detailed_description>Subjects receive Menactra® vaccine study MTA26 ( NCT00643916 ) age-matched Menactra naive participant receive single dose Menactra® Day 0 . They evaluate immunogenicity safety post-vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Inclusion Criteria : Subjects receive one two dos Menactra® vaccine study MTA26 provide blood sample last dose receive At 3 &lt; 6 year age never vaccinate meningococcal disease ( either study vaccine another vaccine ) . Informed consent form sign dated parent ( ) another legally acceptable representative . Subject parent/legal guardian able attend schedule visit comply study procedure . Exclusion Criteria : Participation active ( i.e. , treatment ) portion another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first study vaccination Planned participation another clinical trial present trial period . Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy . Known suspected systemic hypersensitivity vaccine component , history lifethreatening reaction study vaccine product contain substance present study vaccine . Chronic illness stage could interfere trial conduct completion , opinion investigator . Received blood bloodderived product past 3 month . Received vaccine ( desensitization therapy allergy influenza vaccine within 2 week vaccination ) 4 week precede first study vaccination . Planned receipt vaccine within 4 week follow study vaccination . Known human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBs antigen ) , hepatitis C seropositivity . History invasive meningococcal infection ( confirm either clinically , serologically , microbiologically ) . Thrombocytopenia , coagulation disorder , anticoagulant use 3 week precede inclusion contraindicate intramuscular ( IM ) vaccination . Anticipated receive oral inject antibiotic therapy within 72 hour prior trial blood draw . Personal family history GuillainBarré Syndrome ( GBS ) . Any condition , opinion investigator , would pose health risk subject interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcemia</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Menactra®</keyword>
</DOC>